Table 2.
Associations between colorectal cancer and circulating progestagens, a case-cohort analysis from the B~FIT study (1992–2004)
| Progestagen | Q | Case1 n |
HR (95%CI)2 | P for trend3 |
|---|---|---|---|---|
| Pregnenolone | 1 | 46 | Reference | 0.308 |
| 2 | 34 | 0.72 (0.41–1.26) | ||
| 3 | 49 | 0.99 (0.58–1.67) | ||
| 4 | 31 | 0.77 (0.44–1.34) | ||
| 5 | 27 | 0.71 (0.40–1.25) | ||
| Progesterone | 1 | 35 | Reference | 0.461 |
| 2 | 41 | 1.15 (0.66–2.01) | ||
| 3 | 33 | 1.01 (0.56–1.81) | ||
| 4 | 38 | 1.13 (0.64–2.00) | ||
| 5 | 40 | 1.25 (0.71–2.22) | ||
| 17-hydroxypregnenolone | 1 | 40 | Reference | 0.064 |
| 2 | 26 | 0.75 (0.41–1.36) | ||
| 3 | 35 | 0.93 (0.53–1.64) | ||
| 4 | 40 | 1.09 (0.63–1.90) | ||
| 5 | 46 | 1.44 (0.83–2.50) | ||
| 17-hydroxyprogesterone | 1 | 39 | Reference | 0.360 |
| 2 | 33 | 0.83 (0.47–1.48) | ||
| 3 | 31 | 0.65 (0.36–1.16) | ||
| 4 | 44 | 0.95 (0.56–1.61) | ||
| 5 | 40 | 1.13 (0.65–1.97) | ||
| 5α-dihydroprogesterone (5αP) | 1 | 39 | Reference | 0.155 |
| 2 | 39 | 1.20 (0.68–2.12) | ||
| 3 | 44 | 1.14 (0.66–1.96) | ||
| 4 | 40 | 1.19 (0.67–2.12) | ||
| 5 | 25 | 0.67 (0.37–1.21) | ||
| 3α-dihydroprogesterone (3αHP) | 1 | 27 | Reference | 0.212 |
| 2 | 40 | 1.41 (0.79–2.51) | ||
| 3 | 39 | 1.49 (0.84–2.66) | ||
| 4 | 38 | 1.62 (0.90–2.92) | ||
| 5 | 43 | 1.50 (0.83–2.71) | ||
| 20α-dihydroprogesterone (20αHP) | 1 | 34 | Reference | 0.239 |
| 2 | 26 | 0.84 (0.45–1.56) | ||
| 3 | 47 | 1.46 (0.85–2.52) | ||
| 4 | 39 | 1.16 (0.67–2.01) | ||
| 5 | 41 | 1.33 (0.77–2.30) | ||
| Ratios | ||||
| 5αP : progesterone | 1 | 42 | Reference | 0.192 |
| 2 | 39 | 1.07 (0.60–1.90) | ||
| 3 | 42 | 0.86 (0.50–1.48) | ||
| 4 | 32 | 0.77 (0.44–1.35) | ||
| 5 | 32 | 0.77 (0.44–1.33) | ||
| 3αHP : progesterone | 1 | 34 | Reference | 0.945 |
| 2 | 26 | 0.71 (0.39–1.26) | ||
| 3 | 52 | 1.45 (0.84–2.50) | ||
| 4 | 43 | 1.12 (0.64–1.96) | ||
| 5 | 32 | 0.84 (0.46–1.55) | ||
| 20αHP : progesterone | 1 | 36 | Reference | 0.567 |
| 2 | 35 | 0.93 (0.53–1.65) | ||
| 3 | 38 | 1.10 (0.62–1.95) | ||
| 4 | 37 | 1.07 (0.61–1.87) | ||
| 5 | 41 | 1.13 (0.64–2.00) | ||
| 5αP : 3αHP | 1 | 44 | Reference | 0.407 |
| 2 | 37 | 0.97 (0.54–1.72) | ||
| 3 | 34 | 0.82 (0.47–1.45) | ||
| 4 | 39 | 0.95 (0.55–1.63) | ||
| 5 | 33 | 0.78 (0.44–1.37) | ||
| 5αP : 20αHP | 1 | 40 | Reference | 0.137 |
| 2 | 38 | 0.92 (0.54–1.57) | ||
| 3 | 45 | 0.89 (0.51–1.58) | ||
| 4 | 37 | 0.90 (0.52–1.58) | ||
| 5 | 27 | 0.64 (0.36–1.14) | ||
| Progesterone : estradiol4 | 1 | 31 | Reference | 0.970 |
| 2 | 40 | 1.15 (0.65–2.04) | ||
| 3 | 48 | 1.17 (0.66–2.08) | ||
| 4 | 35 | 1.11 (0.59–2.07) | ||
| 5 | 33 | 1.07 (0.57–2.02) |
B~FIT=Breast and Bone Follow-up study to the Fracture Intervention Trial, Q=quintile, n=number, HR=hazard ratio, CI=confidence interval
1
For all hormones/metabolites, there were 99 women from the subcohort in each quintile.
2
Models are adjusted for age, body mass index, clinic enrollment site, and enrollment arm in the original clinical trial.
3
P trend calculated by treating each quintile variable as a continuous exposure (using the median concentrations in each quintile).
4
Measured previously, please see Falk et al. (2015), manuscript reference #14.